08 Nov, EOD - Indian

SENSEX 79486.32 (-0.07)

Nifty 50 24148.2 (-0.21)

Nifty Bank 51561.2 (-0.68)

Nifty IT 42050.15 (0.71)

Nifty Midcap 100 56352 (-1.33)

Nifty Next 50 69774.2 (-1.23)

Nifty Pharma 22542.25 (0.07)

Nifty Smallcap 100 18445.6 (-1.70)

08 Nov, EOD - Global

NIKKEI 225 39500.37 (0.30)

HANG SENG 20728.19 (-1.07)

S&P 6035.5 (0.33)

LOGIN HERE

Piramal Pharma Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 543635 | NSE Symbol : PPLPHARMA | ISIN : INE0DK501011 | Industry : Pharmaceuticals |


Chairman's Speech

Dear Shareholders,

FY2024 has been a strong year for our Company with all-round improvement seen across multiple financial and operational parameters.

During the year, we not only recorded a healthy revenue growth of 15% YoY, but also delivered around 450 basis point YoY improvement in our EBITDA margin. We ended the financial year with a Net Profit After Tax (before exceptional items) of 81 Crores versus a Net Loss (before exceptional items) of 180 Crores in the previous financial year. We also reduced the leverage on our balance sheet from 5.6x Net Debt / EBITDA at the start of the financial year to below 3x by the end of the year. This performance is even more commendable given the backdrop of a challenging macro environment marked by high interest rates, biotech funding challenges, geopolitical tensions leading to supply chain disturbances and slower consumer demand in rural India. We would like to extend our gratitude to all our business partners for their support and our employees and the leadership team for their commitment and hard work, without which we would not have achieved this performance.

10

During the year, we also successfully completed our Rights Issue of 1,050 Crores with a subscription of 128%. We would like to thank our shareholders for their faith in our capabilities and partnering with us in our journey to deliver sustainable shareholder value through consistent and profitable growth.

128%